Introduction
Cancer is the result of multiple genetic mutations and rearrangements, and loss of genetic material. Thus, in theory, it should be an ideal target for gene-replacement therapies. In fact, introduction of single oncosuppressor genes was shown to induce antitumor responses (e.g., apoptosis, growth arrest, differentiation) with no need to correct the multiple mutations that contribute to tumor development (Goyette et al., 1992; Takahashi et al., 1992; Roth and Cristiano, 1997; Favrot et al., 1998) . Among the genes that have been considered for tumor gene replacement, the p53 oncosuppressor gene has received most of the attention, due to its pivotal role in the cell response to DNA damage through the regulation of growth arrest and apoptosis, and to its frequent mutation or inactivation in the majority of human malignancies (Harris, 1996) . A very large number of p53 gene-transfer studies have been performed in vitro and in vivo (Nielsen and Maneval, 1998; Soddu and Sacchi, 1998) . In the absence of vectors that specifically target tumor cells, to bypass potential problems of toxicity due to gene transfer into normal cells, these trials have adopted different routes of intratumor delivery of the p53-carrying vectors. Surprisingly, even the vast majority of the basic and preclinical studies centered on replacement of p53 or other oncosuppressor genes have focused on the effects on cancer cells, while the response of normal cells has been rarely assessed, mostly by using in vitro cultured fibroblasts (Wills et al., 1994; Clayman et al., 1995; Zhang et al., 1995) . Thus, no clear data on p53 toxicity in normal cells in vivo are available. Interestingly, extensive basic studies have shown that, in unstressed cells, the transcription factor p53 is present in a latent state, and is maintained at low levels through targeted degradation. A variety of cellular stresses, including several oncogenic stimuli, stabilize the p53 protein and promote its activation through a series of post-translational modifications (Appella and Anderson, 2000) . These observations revealed the presence of tight mechanisms of p53 regulation that might maintain even an exogenous p53 protein in a latent, inactive state in normal conditions, while activating it in tumor cells. Based on this hypothesis, we previously performed experiments in nontransformed 32D myeloblasts and C2C12 myoblasts, and their relative oncogene-transformed counterparts. We could show that p53 gene transfer induced different suppressing effects in the oncogene-transformed 32D and C2C12 cells, while it was not harmful to their nontransformed, parental cells (Blandino et al., 1995; Soddu et al., 1996; Martinelli et al., 1997; D'Orazi et al., 2000) , or to primary hematopoietic cells in vitro . By biochemical and functional analyses, we also showed that the exogenous p53 protein was significantly more stable and transcriptionally active in the oncogenetransformed C2C12 cells than in their parental counterparts (D'Orazi et al., 2000) . These data suggest that p53 gene transfer might be innocuous to normal cells. Owing to the important implications for cancer gene therapy of these in vitro observations, we sought to verify that p53 gene transfer has no detrimental effects to normal cells in vivo. To this aim, we chose the hematopoietic system for two main reasons. First, the complexity of this system (Domen and Weissman, 1999) , with the variety of cell types that originate from a single stem cell through a composite balance of proliferation, apoptosis, and differentiation events, offers a challenging model to critically test in vivo the safety of p53 gene transfer into normal cells. Second, in the past few years, the technologies for bone marrow (BM) transplantation have progressed significantly in different respects, including ex vivo culture and infection of hematopoietic stem cells (HSC), at least in the mouse model (Karlsson, 1997; Williams et al., 2000) .
Here, we report that murine BM cells infected with a p53 recombinant retrovirus and transplanted into irradiated mice reconstitute the hematopoietic system, without evident alterations in any of its compartments, strongly indicating that p53 gene transfer is not detrimental to normal hematopoietic cells in vivo. Furthermore, we could deplete leukemia cells from normal BM by indiscriminate infection, with the p53-carrying retrovirus, of normal and tumor cells, and let the exogenous p53 protein functionally distinguish between them.
Results

Construction and characterization of p53 recombinant retrovirus for fast ex vivo selection
The Moloney murine leukemia virus-based vector LxSN has been extensively used for infection of hematopoietic cells (Miller et al., 1993) . To minimize the time required for selection, preserving multipotent stem cells in the BM population (Bodine et al., 1991) , the neo gene of the LxSN recombinant retrovirus (Miller and Rosman, 1989) was replaced with the puromycin-resistance gene (Morgesern and Land, 1990 ) (see Experimental procedures). The newly made LxSP vector was then employed to produce replication-defective ecotropic retroviruses for infection of BM cells explanted from 5-fluorouracil (5-FU)-treated mice. We could infect 50-60% of these cells by incubation with a retrovirus suspension in RetroNectint-coated dishes. To ascertain that the LxSP retrovirus could infect hematopoietic progenitors, we performed a long-term in vivo experiment. Mock-infected or LxSP-infected, puromycin-resistant BM cells (1 Â 10 6 per animal) were injected into sublethally irradiated (7 Gy) syngeneic mice. At 2, 4, and 28 weeks posttransplantation, cells from spleen and BM were explanted and tested for their colony-forming ability in the presence of puromycin. Numerous puromycin-resistant colonies were obtained from both the spleen and BM of mice transplanted with LxSP-infected BM cells, while no colonies grew from mice transplanted with mockinfected BM cells (Table 1) . These results indicate that the LxSP recombinant retrovirus can effectively infect primary BM cells, including hematopoietic progenitors, and that such cells can survive and expand in mice up to 7 months post-transplantation.
For the p53 gene transfer experiments, the human wild-type p53 cDNA was cloned into the pLxSP vector (pLp53SP), and p53 protein expression and activity were tested in the p53-sensitive, v-src-transformed 32D myeloid progenitors (32Dv-src) upon retroviral infection. We had previously shown that 32Dv-src cells, when injected intravenously into syngeneic C3H mice, induce a disease closely resembling the clinical manifestations of human acute myeloid leukemia (massive invasion of the BM, splenomegaly, generalized lymphadenopathy, macroscopic or microscopic infiltration of kidneys, liver, and lungs) (Bossi et al., 2000) . Furthermore, p53 gene transfer into 32Dv-src cells by an Lp53SN retroviral vector produced several tumorsuppressing effects in vitro and in vivo, including monocytic differentiation, apoptosis, decreased mortality, and morbidity (Soddu et al., 1996; Bossi et al., 2000) . To test the biological effects of the newly developed Lp53SP retrovirus, 32Dv-src cells were infected with equal amounts of either Lp53SP or LxSP retroviruses, puromycin selected for 48 h, cleaned from debris and dead cells by centrifugation on density gradient, and cultured in vitro for the evaluation of exogenous p53 protein expression, cell survival, proliferation, and differentiation. We found that the Lp53SP-infected 32Dv-src cells: (i) expressed higher levels of p53 protein compared to the mock-and LÂSP-infected controls ( Figure 1a) ; (ii) underwent monocytic differentiation in the absence of added cytokines ( Figure 1b ); (iii) had a reduced proliferation rate ( Figure 1c) ; and (iv) showed reduced viability (Figure 1d ), indicating that the Lp53SP retrovirus delivers a functionally active p53 gene that can reduce the tumorigenic phenotype of the 32Dv-src cells, at least in vitro.
Altogether, these results show that these puromycinselectable recombinant retroviruses can infect longterm-surviving hematopoietic progenitors and transfer a functional p53 gene.
Hematopoietic reconstitution of sublethally irradiated mice by BM cells infected with the Lp53SP retrovirus
Previously, we showed that p53 gene transfer does not affect in vitro survival, proliferation, and differentiation . To evaluate whether the same gene transfer is not detrimental to in vivo hematopoiesis, long-term reconstitution experiments were performed. Primary BM cells from 5-FUtreated mice were infected ex vivo with equal amounts of LxSP or Lp53SP retroviruses. After puromycin selection, we assessed exogenous p53 protein expression by Western blotting (Figure 2a) , and injected the cells into sublethally irradiated (7 Gy) syngeneic mice. Six mice were injected with LxSP-infected-, and six with Lp53SP-infected-BM cells (1 Â 10 6 cells per mouse). At 2 weeks post-transplantation, the spleen and BM from one mouse per group were explanted to evaluate short-term engraftment. Puromycin-resistant cells were present in both mice, indicating engraftment in both groups. Based on this result, we let the remaining mice live for 7 months to ascertain the proliferation and differentiation of the multipotent progenitors. BM cells were then explanted, puromycin-selected, and analysed by flow cytometry with a series of antibodies recognizing the murine antigens of lymphoid and myeloid lineages, or progenitor cells. The expression profiles in the LxSP and These results indicate that infection of BM cells with wild-type p53-carrying retrovirus does not affect the in vivo proliferation and differentiation of the diverse hematopoietic lineages. We next evaluated whether such absence of harmful effects depends on the loss or silencing of the exogenous p53 gene or, as indicated by our previous results in vitro, on the physiological, functional inactivation of the transduced protein (D'Orazi et al., 2000) . In the latter case, the exogenous p53, like the endogenous, would be kept in a latent, inactive form in the absence of stress. To distinguish between these two possibilities, puromycin-selected BM cells from the LxSP and Lp53SP groups were treated with cytosine arabinoside (Ara-C) to activate endogenous and exogenous p53 proteins. Increased sensitivity to Ara-C was observed in the Lp53SP-BM cells compared to controls (Figure 2c ), suggesting that Lp53SP-BM cells were not significantly counterselected in vivo, and that the exogenous p53 protein was functional and could be activated by DNA damage.
Altogether, these data demonstrate that BM cells carrying an exogenous p53 gene maintain the capability to reconstitute the hematopoietic compartment in irradiated mice, strongly indicating that p53 gene transfer is not detrimental for normal hematopoiesis.
Leukemia depletion from BM by indiscriminate infection of normal and tumor cells with Lp53SP retrovirus
To test whether it is possible to deplete tumor contamination from normal cells by p53 gene transfer without tumor-specific targeting (Figure 3 ), 32Dv-src leukemia cells were used as the tumor model, primary BM cells from syngeneic C3H mice as normal counterpart, and irradiated C3H mice as recipients. Sublethally irradiated mice (7 Gy), or mice irradiated with a dose that kills 80% of the animals (8 Gy), were transplanted 2 h after irradiation with a mixture of 32Dv-src, and BM cells infected with either the LxSP or the Lp53SP viruses. We experimentally determined the cell number allowing recovery, after LxSP infection and selection, of at least 5 Â 10 5 BM cells and 5 Â 10 4 32Dv-src cells. In our experimental conditions, these are the numbers needed to reconstitute 100% of the irradiated mice (data not shown), and to induce leukemia in 80% of nonirradiated mice (Bossi et al., 2000) , respectively. Thus, for each of the transplanted mice, 2 Â 10 6 BM cells and 1 Â 10 5 32Dv-src cells were infected in the same medium, rich in cytokines and growth factors. These conditions accelerate the proliferation rate of the 32Dv-src cells that tripled their number in 24 h (Figure 1c ) and increased their retroviral infection efficiency. As expected, after infection and puromycin selection, the viability of 32Dv-src cells was lower in the Lp53SP-infected population than in LxSP-infected control (Figure 4a) . Such difference was due to p53-induced apoptosis, as reported above (Figure 1d ). The less pronounced difference between Lp53SP-and LxSPinfected 32Dv-src cells in the second set of experiments was due to the strong antiapoptotic effects of the cytokines present in the medium. In contrast, no differences were found in the viability of the normal BM cells infected with either of the two retroviruses (Figure 4a) , although less cells survived as the absolute number, due to the lower infection efficiency of these cells compared to the tumor cell line. After removing the dead cells, the pools of BM-and 32Dv-src-infected cells were transplanted into two groups of mice. Half of the Figure 3 Model for BM purging without tumor-specific targeting. The existence of a gene that can functionally discriminate between normal and tumor cells should allow the depletion of leukemia from normal BM cells, by transferring this gene in all cells by an ex vivo gene transfer before transplantation into aplastic mice. If p53 owns these characteristics, the BM cells should reconstitute the hematopoietic compartment of the aplastic mice, and allow the survival of these animals, while the leukemia cells should be suppressed and the mice should not develop leukemia p53 gene transfer without tumor targeting G Bossi et al mice in each group received LxSP-and half Lp53SP-infected cells. No animal died of BM failure in either group. As expected, in the 8-Gy-irradiated mice, the leukemia developed much faster because of the profound immunosuppression of the animals, with a 100% tumor take in the control LxSP mice (Figure 4a , compare the upper and lower panels). During the next 14 months of observation, 10 out of 11 mice (90%) transplanted with the LxSP-infected cells developed and died of leukemia (Figure 4b and c) , as assessed by the presence of splenomegaly, extreme generalized lymphadenopathy, and BM substitution, characteristic findings of 32Dv-src-injected mice (Bossi et al., 2000) . The remaining mouse died 22 months after transplantation, without signs of leukemia or BM failure (data not shown). In contrast, only four out of 11 Lp53SP-transplanted mice (36%) developed leukemia. Moreover, two of these four mice survived significantly longer than the LxSP-treated mice (8 months versus a mean of 4 months in the 7 Gy group, and 9 months versus a mean of 1.5 months in the 8 Gy group) (Figure 4b ), and developed a much less severe disease, as assessed by the absence of splenomegaly and the presence of a modest lymphadenopathy (Figure 4c ). However, BM infiltration by 32Dv-src cells was found in all the four mice. Of the remaining seven mice, four died between 20 and 24 months after transplantation, without any macroscopic signs of disease, and three were killed 24 months after transplantation. Cells were explanted from the spleens, livers, and BM of the killed mice, and cultured in vitro to assess a potential 32Dv-src contamination. None of these animals had evidence of macroscopic tumors, nor the cultured organs presented leukemic cells, as determined in liquid culture by the absence of longterm surviving, cytokine-independent cells (data not shown).
In conclusion, in both groups of irradiated mice, we found that the animals injected with Lp53SP-infected cells survived significantly longer than the controls (Po0.01), and, more importantly, that 80 and 50% of the Lp53SP-treated animals in the 7-and 8-Gyirradiated groups, respectively, did not develop leukemia. Overall, these results show that injection into aplastic mice of a mixture of p53-transduced normal BM cells and leukemia 32Dv-src cells allows reconstitution of the hematopoietic compartment and, concomitantly, suppression of the tumor cells, indicating that exogenous p53 discriminates between normal and tumor cells. These data strongly support the contention that p53 gene transfer can be accomplished with no need for tumor-specific targeting.
Discussion
Here we report that ex vivo infection of primary murine BM cells with a retrovirus encoding wild-type p53 does not modify the ability of HSC to reconstitute the hematopoietic compartment of syngeneic, irradiated mice. This is the first strong indication that p53 gene transfer is not detrimental to normal cells in vivo. We found that, when transplanted into irradiated mice, BM cells infected with a p53-recombinant retrovirus can generate the same lymphomyeloerythroid populations as control-infected BM cells. These results, together with those of the long-term reconstitution experiments we performed, argue against the presence of serious detrimental effects induced in vivo by an exogenous p53 gene. We used puromycin selection to ascertain the presence of the retroviral vectors in the explanted spleen and BM cells. More importantly, the functional persistence of the exogenous p53 gene in the infected populations in vivo was shown by the increased cell sensitivity to p53-activating drugs. These results strongly argue against in vivo counter-selection of cells carrying the exogenous p53 gene. This is in agreement with our previous observations on myoblasts, in which we showed that exogenous p53 can be maintained in a latent, inactive state as the endogenous one, unless stressing stimuli activate both proteins (D'Orazi et al., 2000) . A drawback of our therapeutic strategy could be the development of increased sensitivity of normal cells to drugs that exert their effects through p53-mediated pathways. However, transient expression of the p53 gene was found to be equally efficient in eliminating tumor cells (Roth and Cristiano, 1997) , making its stable integration unnecessary. Indeed, the use made of retroviruses stably integrated into the cell genome was to clearly demonstrate the long-term absence of side effects in normal cells. Interestingly, it has been recently reported that mice with one or two extra copies of the p53 gene develop and age normally (Garcia-Cao et al., 2002) . Our results are in agreement with the feasibility of generating such mice, since the BM cells carrying exogenous p53 genes can normally reconstitute the hematopoietic compartment. However, the success in generating viable and healthy 'Super p53' transgenic mice has been ascribed to the fact that, in contrast to mice carrying heterologous promoter-driven p53 cDNA transgenes, which display serious developmental problems, the 'Super p53' mice carry the p53 transgene as a large genomic fragment. This approach is thought to reproduce the normal expression and regulation of the endogenous gene (Garcia-Cao et al. (2002) and references therein). Since p53 is believed to be mostly regulated at the post-translational level in adult tissues (Appella and Anderson, 2000) , the transgenic data and our results suggest that a tight transcriptional regulation of the p53 gene is indispensable during ontogenesis, but is lost or is much less relevant for cell differentiation in adult mice, at least in hematopoiesis. Alternatively, the hematopoietic system might behave differently from other tissues, and might not require tight regulation of p53 both in ontogenesis and adult life. Several observations indicate a role for p53 in hematopoiesis (Almog and Rotter, 1997) , including increased expression levels during myeloid differentiation (Kastan et al., 1991) , inhibition of myeloid differentiation by impaired p53 activity (Mazzaro et al., 1999) , and induction of differentiation of leukemia cells by wild-type p53 overexpression (Shaulsky et al., 1991) , supporting the first hypothesis. However, further in vivo studies will be necessary to discriminate between the two possibilities and determine whether other adult tissues tolerate p53 gene transfer through classical eucaryotic expression vectors.
For a practical application of our findings, we developed a protocol of ex vivo BM purging from leukemia. We found that ex vivo infection of BM and syngeneic 32Dv-src leukemia cells with a p53-carrying retrovirus allowed reconstitution of the hematopoietic compartment of transplanted mice and, concomitantly, strongly reduced the morbidity and mortality associated with leukemia. These results indicate that p53 gene transfer has a high therapeutic index in mouse leukemia, and opens the possibility of adding this approach to the available purging procedures for hematopoietic cells. Indeed, autologous stem cell transplantation employing marrow or peripheral blood is used to consolidate patients with different types of neoplasia and marrow invasion. However, tumor cell contamination of the reinfused, purged population contributes to tumor relapse (Heslop et al., 1995) , limiting the use of this therapeutic approach to those types of leukemia that undergo complete remission with standard treatments (Gorin, 2002) . Several strategies for purging tumor cells from HSC have been developed. The goal of most of these strategies is gaining tumor specificity through different approaches, including the link of toxins with broad receptor specificity to growth factors, cytokines, or antibody domains, the use of receptor-specific toxins, or the infection with viruses that target HSC poorly, such as the adenovirus for BM purging from breast cancer cells (LaCasse et al. (1999) and references therein). However, these approaches are limited by the scarcity of real tumor-specific antigens, particularly in the hematopoietic system. The possibility of including a strategy that overcomes the need to selectively target tumor cells offers an alternative, or even a synergistic, approach to the current treatments.
Materials and methods
Retroviral vectors and packaging cells
The pLxSN retroviral vector is a Moloney murine leukemia virus-based vector containing the bacterial neo gene downstream of the SV40 early promoter (Miller and Rosman, 1989) . To construct the pLxSP vector, the SV40-puro cassette from the pBabe-puro vector (Morgesern and Land, 1990 ) was excised by BamH1/Xba1 digestion and subcloned into the same sites of the pLxSN vector, with deletion of the SV40-neo cassette. The pLp53SP vector was obtained by inserting the human wt-p53 cDNA and the rabbit b-globin intron from the pCMV-NEO-BAMp53 vector (Baker et al., 1989) into the Hpa1/BamH1 sites of the pLxSP vector.
Virus-producing cells were generated by transient transfection of Phoenix ecotropic packaging cells (kindly provided by Gary Nolan) (Yang et al., 1999) with the retroviral vectors. Retrovirus titers were performed on C2C12 cells with puromycin selection. The viral titers ranged from 5 Â 10 5 to 5 Â 10 6 c.f.u./ml in different experiments.
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Cell cultures
C3H/HeJ female mice (8-week old; Charles River Laboratories Inc., Wilmington, MA, USA) were intravenously injected with 150 mg/kg of 5-FU 2 days before BM cell explantation. Primary BM cells were obtained from the long bones, and cultured as described . For accurate comparisons, the 32Dv-src cells, although growth factor independent (Bodine et al., 1991) , were cultured in the same supplemented medium employed for primary BM cells. Phoenix ecotropic packaging cells were cultured in DMEM medium (GIBCO Invitrogen) supplemented with 10% FBS. For colony formation, cells from BM or spleens were plated in methylcellulose culture mixture (StemCells Technologies, Vancouver, Canada), as previously described . For morphological analysis, cytospin preparations with 4 Â 10 4 cells were fixed and stained with May-Grunwald Giemsa (Sigma, St Louis, MO, USA), and observed with a light microscope.
Retroviral infection
Approximately 1 Â 10 6 primary BM cells were stimulated to proliferate for 2 days in the presence of IL-3, IL-6, and SCF, incubated for 1 h with 8 mg/ml polybrene, and then infected on RetroNectint-coated dishes, following the manufacturer's instructions (Takara Shuzo Co., Otsu, Japan). After infection, BM cells were selected by 48 h incubation in the presence of 2 mg/ml of puromycin (Sigma), followed by centrifugation on the density separation medium Lympholyte-H (Cedarlane Laboratories, Ontario, Canada) to eliminate dead cells.
BM cell transplantation
Female C3H/HeJ mice (10-week old ) were X-irradiated (7 or 8 Gy per mouse) by a Siemens linear accelerator operating at 10 MV, at a rate of 3 Gy/min. At 2 h postirradiation, the mice were intravenously injected with cell suspensions. In the case of purging in the 8-Gy-irradiated mice, a transfusion of fresh BM cells from untreated mice was administered the day after transplantation, to avoid death by marrow aplasia during the 2 weeks following irradiation, since, because of the procedure (i.e., explants and infection of BM cells from 5-FU-treated mice), the transplantation was mainly containing infected BM progenitors which need time for proliferation and differentiation into mature hematopoietic lineages (Domen and Weissman, 1999) .
Western blotting and flow cytometry
Western blot analyses were performed as described (D'Orazi et al., 2000) , by using the rabbit anti-p53 polyclonal serum FL393 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
For flow cytometry, cells were obtained from the BM and spleens, selected by puromycin for 48 h, separated from dead cells by lympholyte-H, and reacted with the following antibodies: rat anti-mouse CD4/L3T4, CD8a/Lyt-2, CD45R/ B220, Ly-6G (GR-1) (all from Southern Biotechnology Associates, Inc., Birmingham, AL, USA), rat anti-mouse CD11b, CD34, CD117 (c-Kit), and Ter-119 (Ly-76) (all from PharMingen, San Diego, CA, USA). Cells were labeled with fluorescein-conjugated goat affinity-purified F(ab 0 ) 2 fragment to rat IgG (H þ L) (Cappel, Durham, NC, USA), and analysed by an Epics XL analyzer (Coulter Corporation).
Statistical analysis
The difference between the pooled survival rates (7 and 8 Gy) of the examined LxSP and Lp53SP populations was evaluated for significance, by means of nonparametric Wilcoxon Rank Sum test.
